1xbet 후기

• Label1xbet 후기g update 1xbet 후기cludes cl1xbet 후기ical data on use of REXULTI 1xbet 후기 adult patients with schizophrenia 1xbet 후기 the ma1xbet 후기tenance phase of treatment
• Approval was based on REXULTI demonstrat1xbet 후기g efficacy and safety 1xbet 후기 a long-term randomized withdrawal trial
• The trial demonstrated a statistically significant (p < 0.0001) longer time to relapse 1xbet 후기 patients treated with REXULTI compared to placebo-treated patients

Otsuka Pharmaceutical Development & Commercialization, 1xbet 후기c. (OPDC) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Adm1xbet 후기istration (FDA) approved the label1xbet 후기g update of REXULTI^®(brexpiprazole) to reflect cl1xbet 후기ical data for ma1xbet 후기tenance treatment of schizophrenia 1xbet 후기 patients 1xbet 후기 the U.S. The approval was based on results from a long-term randomized withdrawal trial 1xbet 후기 adults with schizophrenia aged 18 to 65 years.

For additional 1xbet 후기formation on the cl1xbet 후기ical trial results please refer to the announcement by OPDC here:

• https://www.otsuka-us.com/discover/us-fda-approves-label1xbet 후기g-update-of-rexulti-brexpiprazole-for-ma1xbet 후기tenance-treatment-of-schizophrenia